- Home
- INDP vs GTBP Comparison
INDP vs GTBP Comparison
Compare INDP & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDP
- GTBP
- Stock Information
- Founded
- INDP 2000
- GTBP 1965
- Country
- INDP United States
- GTBP United States
- Employees
- INDP N/A
- GTBP N/A
- Industry
- INDP Biotechnology: Pharmaceutical Preparations
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- INDP Health Care
- GTBP Health Care
- Exchange
- INDP Nasdaq
- GTBP Nasdaq
- Market Cap
- INDP 6.0M
- GTBP 5.5M
- IPO Year
- INDP N/A
- GTBP N/A
- Fundamental
- Price
- INDP $7.30
- GTBP $1.81
- Analyst Decision
- INDP Strong Buy
- GTBP Strong Buy
- Analyst Count
- INDP 2
- GTBP 1
- Target Price
- INDP $238.00
- GTBP $11.00
- AVG Volume (30 Days)
- INDP 24.5K
- GTBP 107.3K
- Earning Date
- INDP 08-11-2025
- GTBP 08-13-2025
- Dividend Yield
- INDP N/A
- GTBP N/A
- EPS Growth
- INDP N/A
- GTBP N/A
- EPS
- INDP N/A
- GTBP N/A
- Revenue
- INDP N/A
- GTBP N/A
- Revenue This Year
- INDP N/A
- GTBP N/A
- Revenue Next Year
- INDP N/A
- GTBP N/A
- P/E Ratio
- INDP N/A
- GTBP N/A
- Revenue Growth
- INDP N/A
- GTBP N/A
- 52 Week Low
- INDP $7.30
- GTBP $1.72
- 52 Week High
- INDP $59.36
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- INDP 31.62
- GTBP 32.46
- Support Level
- INDP $8.00
- GTBP $2.01
- Resistance Level
- INDP $10.57
- GTBP $2.11
- Average True Range (ATR)
- INDP 0.79
- GTBP 0.15
- MACD
- INDP -0.43
- GTBP -0.01
- Stochastic Oscillator
- INDP 0.00
- GTBP 5.88
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.